

HHCS Human Hepatocytes Cryopreserved for Suspension Assays
Cell Specification – Certificate of Analysis (CoA)

Lot HH160512-3

Batch Release: June 02, 2023

Donor data

Species: Human

Gender: female

Age: 73 years

Diagnosis: Metastasis of Sigmacarcinoma
Medical History: Diabetes, Hypertension
Therapy: segment resection liver S7/ S8
Serology: HAV, HBV, HCV, HIV 1/2: negative

Medication: Enalapril (10 mg), Bisoprolol (5 mg), Omeprazol (40 mg),
Metformin (500 mg, break), Dopegyt (500 mg),
Lercanidipin (20 mg)

Cryopreservation and Thawing

Cryopreservation:

Date: May 12, 2016
Amount per vial: 10.3×10^6 cells

Thawing:

Post-thaw viability: 77.6 %
Post-thaw yield per vial: 4.72×10^6 cells
Recovery: 45.8 %

Suspension culture

Viability test on orbital shaker (100-150 rpm at room temperature with 0.54×10^6 cells in 0.5 ml HPM-Cryo):

Time (h)	0	1	2
Viability (%)	77.6	71.0	62.8

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: M. Thiede

Verified by: K. Damrau